Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer

Show simple item record

dc.contributor.author Eurola, Annika
dc.contributor.author Ristimäki, Ari
dc.contributor.author Mustonen, Harri
dc.contributor.author Nurmi, Anna-Maria
dc.contributor.author Hagström, Jaana
dc.contributor.author Haglund, Caj
dc.contributor.author Seppänen, Hanna
dc.date.accessioned 2021-08-11T09:29:01Z
dc.date.available 2021-08-11T09:29:01Z
dc.date.issued 2021-05-10
dc.identifier.citation Eurola , A , Ristimäki , A , Mustonen , H , Nurmi , A-M , Hagström , J , Haglund , C & Seppänen , H 2021 , ' Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer ' , Scientific Reports , vol. 11 , no. 1 , 9896 . https://doi.org/10.1038/s41598-021-89134-2
dc.identifier.other PURE: 167375557
dc.identifier.other PURE UUID: d7ce5972-06c6-4fa9-a0c0-a6225af0ceae
dc.identifier.other WOS: 000658744700025
dc.identifier.other ORCID: /0000-0001-6079-7881/work/98374084
dc.identifier.other ORCID: /0000-0001-5632-6796/work/98374873
dc.identifier.uri http://hdl.handle.net/10138/333053
dc.description.abstract Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigated whether podocalyxin expression correlates with treatment response or survival in neoadjuvant-treated PDAC. Through immunohistochemistry, we evaluated podocalyxin expression in 88 neoadjuvant and 143 upfront surgery patients using two antibodies. We developed a six-tier grading scheme for neoadjuvant responses evaluating the remaining tumor cells in surgical specimens. Strong podocalyxin immunopositivity associated with poor survival in the patients responding poorly to the neoadjuvant treatment (HR 4.16, 95% CI 1.56-11.01, p=0.004), although neoadjuvant patients exhibited generally low podocalyxin expression (p=0.017). Strong podocalyxin expression associated with perineural invasion (p=0.003) and lack of radiation (p=0.036). Two patients exhibited a complete neoadjuvant response, while a strong neoadjuvant response ( en
dc.format.extent 11
dc.language.iso eng
dc.relation.ispartof Scientific Reports
dc.rights cc_by
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject HUMAN PROTEIN ATLAS
dc.subject POOR-PROGNOSIS
dc.subject DUCTAL ADENOCARCINOMA
dc.subject MAJOR SIALOPROTEIN
dc.subject EXPRESSION
dc.subject SURVIVAL
dc.subject CHEMORADIOTHERAPY
dc.subject CHEMORADIATION
dc.subject GEMCITABINE
dc.subject VALIDATION
dc.subject 3122 Cancers
dc.title Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer en
dc.type Article
dc.contributor.organization CAN-PRO - Translational Cancer Medicine Program
dc.contributor.organization Department of Surgery
dc.contributor.organization Faculty of Medicine
dc.contributor.organization University of Helsinki
dc.contributor.organization Helsinki University Hospital Area
dc.contributor.organization Department of Pathology
dc.contributor.organization HUSLAB
dc.contributor.organization HUS Diagnostic Center
dc.contributor.organization HUS Abdominal Center
dc.contributor.organization Clinicum
dc.contributor.organization Medicum
dc.contributor.organization II kirurgian klinikka
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1038/s41598-021-89134-2
dc.relation.issn 2045-2322
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
s41598_021_89134_2.pdf 1.314Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record